Top

Current Hematologic Malignancy Reports

Published in:

01-12-2019 | Acute Myeloid Leukemia | Acute Myeloid Leukemias (H Erba, Section Editor)

Health-Related Quality of Life and Treatment of Older Adults with Acute Myeloid Leukemia: a Young International Society of Geriatric Oncology Review Paper

Authors: Kah Poh Loh, Maya Abdallah, Anita J. Kumar, Nina R Neuendorff, Saurabh Dahiya, Heidi D. Klepin

Published in: Current Hematologic Malignancy Reports | Issue 6/2019

Abstract

Purpose of Review

The treatment landscape for older patients with acute myeloid leukemia (AML) is evolving. Many treatments have comparable efficacy making their impact on quality of life (QoL) an important differentiating factor. In this review, we discuss QoL in older adults with AML, focusing on therapeutic and observational trials that have incorporated QoL assessments.

Recent Findings

Health-related quality of life (HRQoL) is a multi-dimensional concept incorporating physical, mental, emotional, and social functioning domains. HRQoL components overlap with components of geriatric assessment, a multidisciplinary diagnostic process that identifies underlying vulnerabilities of older adults and guides subsequent management strategies. HRQoL questionnaires may be general, cancer-specific, leukemia-specific, or symptom-focused. Therapeutic and observational cohort studies suggest HRQoL improves, or at least remains stable, during intensive and lower-intensity therapies. Nonetheless, HRQoL is not routinely incorporated in AML therapeutic trials.

Summary

HRQoL assessments can inform both decision-making and management for older adults with AML.

SEER Cancer Statistics Factsheets: Acute myeloid leukemia. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/amyl.html. Accessed 25 Aug 2019.

Lubbert M, Ruter BH, Claus R, Schmoor C, Schmid M, Germing U, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97(3):393–401.PubMedPubMedCentral

Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–7.PubMedPubMedCentral

Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–9.PubMedPubMedCentral

Ustun C, Lazarus HM, Weisdorf D. To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century. Bone Marrow Transplant. 2013;48(12):1497–505.PubMed

• Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130(9):1156–64 More older adults are receiving allogeneic hematopoietic cell transplantation. PubMedPubMedCentral

•• Loh KP, Mohile SG, Epstein RM, McHugh C, Flannery M, Culakova E, et al. Willingness to bear adversity and beliefs about the curability of advanced cancer in older adults. Cancer. 2019;125(14):2506–13 Older adults with cancer value quality of life as much as survival. PubMed

•• Soto-Perez-De-Celis E, Li D, Sun CL, Kim H, Twardowski P, Fakih M, et al. Patient-defined goals and preferences among older adults with cancer starting chemotherapy (CT). J Clin Oncol. 2018;36(suppl; abstr 10048) Outcomes such as cognitive function are important to older adults.

Ferrell BR, Dow KH, Grant M. Measurement of the quality of life in cancer survivors. Qual Life Res. 1995;4(6):523–31.PubMed

10.

Alibhai SM, Leach M, Kowgier ME, Tomlinson GA, Brandwein JM, Minden MD. Fatigue in older adults with acute myeloid leukemia: predictors and associations with quality of life and functional status. Leukemia. 2007;21(4):845–8.PubMed

11.

Santos FR, Kozasa EH, Chauffaille Mde L, Colleoni GW, Leite JR. Psychosocial adaptation and quality of life among Brazilian patients with different hematological malignancies. J Psychosom Res. 2006;60(5):505–11.PubMed

12.

Servaes P, Verhagen CA, Bleijenberg G. Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: daily self-report and objective behavior. Cancer. 2002;95(9):2017–26.PubMed

13.

Loh KP, Zittel J, Kadambi S, Pandya C, Xu H, Flannery M, et al. Elucidating the associations between sleep disturbance and depression, fatigue, and pain in older adults with cancer. J Geriatr Oncol. 2018;9(5):464–8.PubMed

14.

Syrjala KL, Stover AC, Yi JC, Artherholt SB, Abrams JR. Measuring social activities and social function in long-term cancer survivors who received hematopoietic stem cell transplantation. Psychooncology. 2010;19(5):462–71.PubMedPubMedCentral

15.

Selivanova A, Buskens E, Krabbe PFM. Head-to-head comparison of EQ-5D-3L and EQ-5D-5L health values. Pharmacoeconomics. 2018;36(6):715–25.PubMedPubMedCentral

16.

Hulme C, Long AF, Kneafsey R, Reid G. Using the EQ-5D to assess health-related quality of life in older people. Age Ageing. 2004;33(5):504–7.PubMed

17.

Barile JP, Horner-Johnson W, Krahn G, Zack M, Miranda D, DeMichele K, et al. Measurement characteristics for two health-related quality of life measures in older adults: the SF-36 and the CDC healthy days items. Disabil Health J. 2016;9(4):567–74.PubMedPubMedCentral

18.

Reulen RC, Zeegers MP, Jenkinson C, Lancashire ER, Winter DL, Jenney ME, et al. The use of the SF-36 questionnaire in adult survivors of childhood cancer: evaluation of data quality, score reliability, and scaling assumptions. Health Qual Life Outcomes. 2006;4:77.PubMedPubMedCentral

19.

Blaes AH, Ma L, Zhang Y, Peterson BA. Quality of life appears similar between survivors of indolent and aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2011;52(11):2105–10.PubMedPubMedCentral

20.

Horner-Johnson W, Krahn GL, Suzuki R, Peterson JJ, Roid G, Hall T, et al. Differential performance of SF-36 items in healthy adults with and without functional limitations. Arch Phys Med Rehabil. 2010;91(4):570–5.PubMed

21.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.PubMed

22.

Wheelwright S, Darlington AS, Fitzsimmons D, Fayers P, Arraras JI, Bonnetain F, et al. International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer. Br J Cancer. 2013;109(4):852–8.PubMedPubMedCentral

23.

Yilmaz M, Cengiz HO. The relationship between spiritual well-being and quality of life in cancer survivors. Palliat Support Care. 2019:1–8.

24.

Overcash J, Extermann M, Parr J, Perry J, Balducci L. Validity and reliability of the FACT-G scale for use in the older person with cancer. Am J Clin Oncol. 2001;24(6):591–6.PubMed

25.

Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol. 1984;2(5):472–83.PubMed

26.

Ganz PA, Haskell CM, Figlin RA, La Soto N, Siau J. Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index--Cancer. Cancer. 1988;61(4):849–56.PubMed

27.

Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1(6):778–84.PubMedPubMedCentral

28.

Kelly CM, Shahrokni A. Moving beyond Karnofsky and ECOG performance status assessments with new technologies. J Oncol. 2016;2016:6186543.PubMedPubMedCentral

29.

Mackworth N, Fobair P, Prados MD. Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores. J Neuro-Oncol. 1992;14(3):243–53.

30.

Khan L, Cramarossa G, Lemke M, Nguyen J, Zhang L, Chen E, et al. Symptom clusters using the Spitzer quality of life index in patients with brain metastases--a reanalysis comparing different statistical methods. Support Care Cancer. 2013;21(2):467–73.PubMed

31.

Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis. 1981;34(12):585–97.PubMed

32.

Stein KD, Denniston M, Baker F, Dent M, Hann DM, Bushhouse S, et al. Validation of a modified Rotterdam symptom checklist for use with cancer patients in the United States. J Pain Symptom Manag. 2003;26(5):975–89.

33.

Hardy JR, Edmonds P, Turner R, Rees E, A'Hern R. The use of the Rotterdam Symptom Checklist in palliative care. J Pain Symptom Manag. 1999;18(2):79–84.

34.

Peruselli C, Camporesi E, Colombo AM, Cucci M, Mazzoni G, Paci E. Quality-of-life assessment in a home care program for advanced cancer patients: a study using the Symptom Distress Scale. J Pain Symptom Manag. 1993;8(5):306–11.

35.

Zebrack BJ, Chesler MA. A psychometric analysis of the Quality of Life-Cancer Survivors (QOL-CS) in survivors of childhood cancer. Qual Life Res. 2001;10(4):319–29.PubMed

36.

Cella D, Jensen SE, Webster K, Hongyan D, Lai JS, Rosen S, et al. Measuring health-related quality of life in leukemia: the functional assessment of cancer therapy--leukemia (FACT-Leu) questionnaire. Value Health. 2012;15(8):1051–8.PubMed

37.

Mamolo CM, Cappelleri JC, Hoang CJ, Kim R, Hadfield A, Middleton C, et al. A real-world, cross-sectional, community survey of symptoms and health-related quality of life of adults with acute myeloid leukemia. Future Oncol. 2019;15(16):1895–909.PubMed

38.

Meng Q, Yang Z, Wu Y, Xiao Y, Gu X, Zhang M, et al. Reliability analysis of the Chinese version of the functional assessment of cancer therapy - leukemia (FACT-Leu) scale based on multivariate generalizability theory. Health Qual Life Outcomes. 2017;15(1):93.PubMedPubMedCentral

39.

McQuellon RP, Russell GB, Cella DF, Craven BL, Brady M, Bonomi A, et al. Quality of life measurement in bone marrow transplantation: development of the functional assessment of cancer therapy-bone marrow transplant (FACT-BMT) scale. Bone Marrow Transplant. 1997;19(4):357–68.PubMed

40.

Barata A, Martino R, Gich I, Garcia-Cadenas I, Abella E, Barba P, et al. Do patients and physicians agree when they assess quality of life? Biol Blood Marrow Transplant. 2017;23(6):1005–10.PubMed

41.

Soudy H, Maghfoor I, Elhassan TAM, Abdullah E, Rauf SM, Al Zahrani A, et al. Translation and validation of the functional assessment of cancer therapy-bone marrow transplant (FACT-BMT) version 4 quality of life instrument into Arabic language. Health Qual Life Outcomes. 2018;16(1):47.PubMedPubMedCentral

42.

Watson M, Zittoun R, Hall E, Solbu G, Wheatley K. A modular questionnaire for the assessment of longterm quality of life in leukaemia patients: the MRC/EORTC QLQ-LEU. Qual Life Res. 1996;5(1):15–9.PubMed

43.

Oliva EN, Nobile F, Alimena G, Ronco F, Specchia G, Impera S, et al. Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. Haematologica. 2011;96(5):696–702.PubMedPubMedCentral

44.

Wagner LI, Beaumont JL, Ding B, Malin J, Peterman A, Calhoun E, et al. Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the functional assessment of cancer therapy-neutropenia (FACT-N). Support Care Cancer. 2008;16(1):47–56.PubMed

45.

Signorovitch J, Brainsky A, Grotzinger KM. Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia. Qual Life Res. 2011;20(10):1737–44.PubMed

46.

Khelif A, Saleh MN, Salama A, Portella M, Duh MS, Ivanova J, et al. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: findings from the EXTEND study. Am J Hematol. 2019;94(2):200–8.PubMed

47.

Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3 Suppl 2):13–9.PubMed

48.

Williams LA, Ahaneku H, Cortes JE, Garcia Manero G, Kantarjian HM, Shi Q, et al. Comparison of symptom burden in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blood. 2014;124(21):2652.

49.

•• Loh KP, Soto-Perez-de-Celis E, Hsu T, de Glas NA, Battisti NML, Baldini C, et al. What every oncologist should know about geriatric assessment for older patients with cancer: Young International Society of Geriatric Oncology Position Paper. J Oncol Pract. 2018;14(2):85–94 Practical information on how to conduct geriatric assessment for older adults with cancer. PubMedPubMedCentral

50.

Asakawa T, Koyano W, Ando T, Shibata H. Effects of functional decline on quality of life among the Japanese elderly. Int J Aging Hum Dev. 2000;50(4):319–28.PubMed

51.

Jonsén Elisabeth LG, Jónsson Palmi V. Gösta Bucht Functional status in elderly people after acute care and quality of life at oneyear followup. Health Sci J. 2014:35–48.

52.

Deschler B, Ihorst G, Platzbecker U, Germing U, Marz E, de Figuerido M, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98(2):208–16.PubMedPubMedCentral

53.

Sherman AE, Motyckova G, Fega KR, Deangelo DJ, Abel GA, Steensma D, et al. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res. 2013;37(9):998–1003.PubMedPubMedCentral

54.

Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121(21):4287–94.PubMedPubMedCentral

55.

Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99(8):1373–9.PubMedPubMedCentral

56.

Snyder CF, Blackford AL, Sussman J, Bainbridge D, Howell D, Seow HY, et al. Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients' supportive care needs. Qual Life Res. 2015;24(5):1207–16.PubMed

57.

Nimako K, Ayite B, Priest K, Severn J, Fries HM, Gunapala R, et al. A randomised assessment of the use of a quality of life questionnaire with or without intervention in patients attending a thoracic cancer clinic. Eur J Cancer Care (Engl). 2017;26(4).

58.

•• Mohile SG, Epstein RM, Hurria A, Heckler CE, Duberstein P, Canin BE, et al. Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute Community Oncology Research Program. J Clin Oncol. 2019;7:1–9. https://doi.org/10.1001/jamaoncol.2019.4728. Geriatric assessment and geriatric assessment-guided recommendations improve communication with older patients.

59.

Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004;18(4):809–16.PubMed

60.

• El-Jawahri A, Nelson-Lowe M, VanDusen H, Traeger L, Abel GA, Greer JA, et al. Patient-clinician discordance in perceptions of treatment risks and benefits in older patients with acute myeloid leukemia. Oncologist. 2019;24(2):247–54 Health-related quality of life may be associated with misconception of prognosis, and assessing HRQoL may help with prognostic discussions. PubMed

61.

Allen J, Alpass FM, Stephens CV. The sensitivity of the MOS SF-12 and PROMIS(R) global summary scores to adverse health events in an older cohort. Qual Life Res. 2018;27(8):2207–15.PubMed

62.

Moffatt S, White M, Mackintosh J, Howel D. Using quantitative and qualitative data in health services research - what happens when mixed method findings conflict? [ISRCTN61522618]. BMC Health Serv Res. 2006;6:28.PubMedPubMedCentral

63.

Feemster LC, Cooke CR, Rubenfeld GD, Hough CL, Ehlenbach WJ, Au DH, et al. The influence of hospitalization or intensive care unit admission on declines in health-related quality of life. Ann Am Thorac Soc. 2015;12(1):35–45.PubMedPubMedCentral

64.

Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562–9.PubMed

65.

Mohamedali H, Breunis H, Timilshina N, Brandwein JM, Gupta V, Minden MD, et al. Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia. Leuk Res. 2012;36(10):1241–8.PubMed

66.

Alibhai SM, Breunis H, Timilshina N, Brignardello-Petersen R, Tomlinson G, Mohamedali H, et al. Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age. J Geriatr Oncol. 2015;6(4):262–71.PubMed

67.

•• Klepin HD, Tooze JA, Pardee TS, Ellis LR, Berenzon D, Mihalko SL, et al. Effect of intensive chemotherapy on physical, cognitive, and emotional health of older adults with acute myeloid leukemia. J Am Geriatr Soc. 2016;64(10):1988–95 Declines in physical function persist even after intensive chemotherapy in older adults with acute myeloid leukemia. PubMedPubMedCentral

68.

Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987–96.PubMed

69.

Kornblith AB, Herndon JE 2nd, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20(10):2441–52.PubMed

70.

Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers EL, et al. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013;98(1):119–28.PubMedPubMedCentral

71.

Estey EH. How I treat older patients with AML. Blood. 2000;96(5):1670–3.PubMed

72.

•• El-Jawahri A, Abel GA, Traeger L, Waldman L, Markovitz N, VanDusen H, et al. Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia. 2019;33(10):2393–402 QoL and mood trajectories are similar in older adults receiving intensive and non-intensive chemotherapy. PubMed

73.

• Cheng MJ, Smith BD, Hourigan CS, Gojo I, Pratz KW, Blackford AL, et al. A single center survey of health-related quality of life among acute myeloid leukemia survivors in first complete remission. J Palliat Med. 2017;20(11):1267–73 Quality of life is relevant to younger patients with acute myeloid leukemia. PubMedPubMedCentral

74.

Leunis A, Redekop WK, Uyl-de Groot CA, Lowenberg B. Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study. Eur J Haematol. 2014;93(3):198–206.PubMed

75.

El-Jawahri AR, Abel GA, Steensma DP, LeBlanc TW, Fathi AT, Graubert TA, et al. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015;121(16):2840–8.PubMedPubMedCentral

76.

• Slavin SD, Fenech A, Jankowski AL, Abel GA, Brunner AM, Steensma DP, et al. Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer. 2019;125(21):3845–52 Almost one-third of older adults with acute myeloid leukemia are admitted to intensive care units during their initial diagnosis. PubMed

77.

LeBlanc TW, Wolf SP, El-Jawahri A, Davis DM, Locke SC, Abernethy A. Symptom burden, quality of life, and distress in acute myeloid leukemia patients receiving induction chemotherapy: results of a prospective electronic patient-reported outcomes study. Blood. 2015;126(23):4496.

78.

Temel JS, Greer JA, Admane S, Gallagher ER, Jackson VA, Lynch TJ, et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol. 2011;29(17):2319–26.PubMed

79.

Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–42.

80.

•• El-Jawahri A, LeBlanc T, VanDusen H, Traeger L, Greer JA, Pirl WF, et al. Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. JAMA. 2016;316(20):2094–103 Inpatient palliative care during hematopoetic stem cell transplantation improves quality of life. PubMedPubMedCentral

81.

Alibhai SM, Durbano S, Breunis H, Brandwein JM, Timilshina N, Tomlinson GA, et al. A phase II exercise randomized controlled trial for patients with acute myeloid leukemia undergoing induction chemotherapy. Leuk Res. 2015. https://doi.org/10.1016/j.leukres.2015.08.012.

82.

Alibhai SM, O’Neill S, Fisher-Schlombs K, Breunis H, Brandwein JM, Timilshina N, et al. A clinical trial of supervised exercise for adult inpatients with acute myeloid leukemia (AML) undergoing induction chemotherapy. Leuk Res. 2012;36(10):1255–61.PubMedPubMedCentral

83.

Klepin HD, Danhauer SC, Tooze JA, Stott K, Daley K, Vishnevsky T, et al. Exercise for older adult inpatients with acute myelogenous leukemia: a pilot study. J Geriatr Oncol. 2011;2(1):11–7.PubMedPubMedCentral

84.

Galway K, Black A, Cantwell M, Cardwell CR, Mills M, Donnelly M. Psychosocial interventions to improve quality of life and emotional wellbeing for recently diagnosed cancer patients. Cochrane Database Syst Rev. 2012;11:Cd007064.PubMed

85.

Parsons SK, Rodday AM, Bush R, Pei Q, Waheed A, Keller FG, et al. Health-related quality of life (HRQL) trajectories during treatment for advanced stage pediatric Hodgkin lymphoma (HL). Blood. 2018;132(Suppl 1):3587.

86.

Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–305.PubMed

87.

Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, et al. Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. Clin Trials. 2018;15(6):624–30.PubMed

Title: Health-Related Quality of Life and Treatment of Older Adults with Acute Myeloid Leukemia: a Young International Society of Geriatric Oncology Review Paper
Authors: Kah Poh Loh
Maya Abdallah
Anita J. Kumar
Nina R Neuendorff
Saurabh Dahiya
Heidi D. Klepin
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Acute Myeloid Leukemia
Geriatric Assessment
Leukemia
Published in: Current Hematologic Malignancy Reports / Issue 6/2019
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-019-00552-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Health-Related Quality of Life and Treatment of Older Adults with Acute Myeloid Leukemia: a Young International Society of Geriatric Oncology Review Paper

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 6/2019

Driving the CAR to the Bone Marrow Transplant Program

The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS)

The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?

Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice

Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO

Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page